Celebrating our 25th anniversary
Fresenius Medical Care was formed 25 years ago, and we are now the world’s largest dialysis provider. Join us as we celebrate our achievements and look ahead to the next 25 years of possibilities. For patients. For employees. For healthcare.
Fresenius Medical Care North America (FMCNA) was formed with the merger of Fresenius USA, Inc., and National Medical Care’s North American dialysis business, becoming the continent’s leading dialysis provider and renal products manufacturer.
Entered the renal pharmaceuticals market with the acquisition of phosphate binder PhosLo®. PhosLo is a calcium acetate phosphate binder for oral application in end stage renal disease patients.
Acquired dialysis provider Renal Care Group, a specialized dialysis services company that provided care to patients with kidney disease.
Entered into a licensing agreement for Venofer® to treat iron deficiency anemia experienced by dialysis patients.
Fresenius Renal Pharmaceuticals launched an authorized generic equivalent of PhosLo in partnership with Sandoz Pharmaceutical company.
Acquired Nashville-based Health IT Services Group, bringing Acumen nEHR — the first nephrology-specific electronic health record — into the organization.
Extended cooperation with pharmaceutical company Galencia and founded Vifor Fresenius Medical Care Renal Pharma (VFMCRP), to develop and market pharmaceutical therapies for patients with chronic kidney disease.
Fresenius Renal Pharmaceuticals launched Velphoro®, a phosphate binder used in the treatment of hyperphosphatemia in patients who receive dialysis.
Renal Therapies Group introduced the CLiC™ device, part of the Crit-Line® technology product line. The CLiC device non-invasively measures hematocrit, oxygen saturation, and percent change in intravascular blood volume during a patient’s hemodialysis treatment.
During a record-setting hurricane season, our Disaster Response Team mobilized ahead of hurricanes Irma, Harvey, and Maria, ensuring our dialysis patients received the life-sustaining care they needed and our employees were safe and supported.
Launched Fresenius Kidney Care’s kidney disease education class, a free, expert-led class that helps people learn more about kidney disease and their treatment options — including transplant and home dialysis.
Renal Therapies Group launched the 2008T BlueStar™ hemodialysis machine across the U.S., providing the most comprehensive upgrade in company history with evolved technology and elevated performance.
Expanded collaboration with Humana to improve the health of eligible Humana Medicare Advantage and commercial members with chronic kidney disease and end stage renal disease through more coordinated, holistic care.
Provided support to our employees during COVID-19 including child care stipends, supplemental pay, as well as procuring personal protective equipment well in advance of the onset of the pandemic.
Fresenius Kidney Care announced plans to open more than 100 new Transitional Care Units to help people recently diagnosed with kidney failure learn about available treatment options, including home dialysis.
The National Intensive Renal Care Reserve was formed in response to COVID-19, to provide additional dialysis machines for the nation’s hospitals due to an increase in patients with acute kidney injury.
For the fifth consecutive year, Fresenius Kidney Care demonstrated its continued success in achieving 5-Diamond status in all participating dialysis centers, reinforcing our commitment to promote, enhance, and raise awareness about the importance of safety.
COVID-19 vaccines allocated to dialysis centers nationwide to support people with kidney failure who are at a high risk of complications from COVID-19. The plan also addressed health equity by reaching a high percentage of ethnic minorities with chronic kidney disease.
Renal Therapies Group’s customer support team named a J.D. Power Certified Customer Service Program recipient for 2020.*
*Fresenius Renal Therapies Group has been recognized by J.D. Power for providing "An Outstanding Customer Service Experience for Phone Support.”
Renal Therapies Group introduced the Kinexus™ Therapy Management Platform, a cloud-based connected health platform that supports the management of home peritoneal dialysis therapy for patients using the Liberty® Select cycler.
Our innovative Fresenius Kidney Care nurse residency program announced a milestone of 175 graduates, with 250 nurses on track for 2021 and 500 in 2022. The development program is for graduate nurses and is the first of its kind in dialysis.